A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer.

J Exp Clin Cancer Res · 2020 · PMC7216678 · PMID 32398042

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Compared to PRLR-DbsAb alone, the combination with PD-1 mAb group showed an increasing trend of cytotoxicity without significant difference (Fig. 7 f).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.